IL143040A0 - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state

Info

Publication number
IL143040A0
IL143040A0 IL14304099A IL14304099A IL143040A0 IL 143040 A0 IL143040 A0 IL 143040A0 IL 14304099 A IL14304099 A IL 14304099A IL 14304099 A IL14304099 A IL 14304099A IL 143040 A0 IL143040 A0 IL 143040A0
Authority
IL
Israel
Prior art keywords
meta
stable crystalline
crystalline region
producing particles
particles
Prior art date
Application number
IL14304099A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL143040A0 publication Critical patent/IL143040A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14304099A 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state IL143040A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (1)

Publication Number Publication Date
IL143040A0 true IL143040A0 (en) 2002-04-21

Family

ID=20413377

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14304099A IL143040A0 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Country Status (27)

Country Link
US (1) US6475524B1 (de)
EP (1) EP1133285B1 (de)
JP (1) JP4447169B2 (de)
KR (1) KR100697780B1 (de)
CN (1) CN1198592C (de)
AT (1) ATE318583T1 (de)
AU (1) AU767313B2 (de)
BR (1) BR9915592A (de)
CA (1) CA2349633C (de)
CY (1) CY1105609T1 (de)
CZ (1) CZ20011778A3 (de)
DE (1) DE69930158T2 (de)
DK (1) DK1133285T3 (de)
EE (1) EE200100275A (de)
ES (1) ES2258865T3 (de)
HU (1) HUP0104182A2 (de)
IL (2) IL143040A0 (de)
IS (1) IS5946A (de)
NO (1) NO20012514L (de)
NZ (1) NZ511494A (de)
PL (1) PL348523A1 (de)
PT (1) PT1133285E (de)
SE (1) SE9804000D0 (de)
SK (1) SK7032001A3 (de)
TR (1) TR200101424T2 (de)
WO (1) WO2000030614A1 (de)
ZA (1) ZA200103946B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (de) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Poröse substanz und verfahren zu ihrer herstellung
EP1401563B2 (de) * 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Verfahren zur herstellung von nano- und mikro-teilchen
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1753734A1 (de) 2004-05-05 2007-02-21 Renopharm Ltd. Stickstoffmonoxidspender und anwendungen davon
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
US8585943B2 (en) * 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
ES2170853T3 (es) 1995-03-28 2002-08-16 Fidia Advanced Biopolymers Srl Nanosferas que comprenden un polisacarido biocompatible.
EP1393721B1 (de) 1997-03-20 2008-11-26 Schering Corporation Dosierungsform eines Pulveragglomerates

Also Published As

Publication number Publication date
SE9804000D0 (sv) 1998-11-23
CY1105609T1 (el) 2010-07-28
KR20010080534A (ko) 2001-08-22
NZ511494A (en) 2003-11-28
KR100697780B1 (ko) 2007-03-21
IS5946A (is) 2001-05-18
JP2002530319A (ja) 2002-09-17
BR9915592A (pt) 2001-08-07
TR200101424T2 (tr) 2001-12-21
US6475524B1 (en) 2002-11-05
HUP0104182A2 (hu) 2002-03-28
ZA200103946B (en) 2002-10-30
IL143040A (en) 2009-09-01
DE69930158T2 (de) 2006-11-16
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
AU767313B2 (en) 2003-11-06
NO20012514D0 (no) 2001-05-22
JP4447169B2 (ja) 2010-04-07
SK7032001A3 (en) 2001-11-06
CA2349633C (en) 2009-06-02
PT1133285E (pt) 2006-06-30
DE69930158D1 (de) 2006-04-27
CN1198592C (zh) 2005-04-27
WO2000030614A1 (en) 2000-06-02
ES2258865T3 (es) 2006-09-01
CZ20011778A3 (cs) 2001-08-15
PL348523A1 (en) 2002-06-03
EP1133285B1 (de) 2006-03-01
EE200100275A (et) 2002-10-15
AU2010400A (en) 2000-06-13
NO20012514L (no) 2001-07-19
CA2349633A1 (en) 2000-06-02
EP1133285A1 (de) 2001-09-19
DK1133285T3 (da) 2006-06-06

Similar Documents

Publication Publication Date Title
PL348523A1 (en) A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
CA2348084A1 (en) Crystallisation using supercritical or subcritical fluids
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
BR0008059A (pt) Composições de valdecoxib
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
HUT63763A (en) Process for producing pharmaceutical composition comprising rapamycin, suitable for treating ophthalmia
CA2205546A1 (en) Oral compositions containing ondansetron
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
NO20002702L (no) Tienopyrimidiner
CA2198706A1 (en) Methods for the treatment of inflammatory joint disease
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
WO2002002056A3 (en) Method of treatment of seborrheic dermatitis
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
MY131878A (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
NO903384D0 (no) Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-urinstoffer og -tiourinstoffer og derivater derav.
WO2003049667A3 (en) The method of treating cancer
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2004014391B1 (en) Use of carboxamides for the treatment of tinnitus
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
TW202617141A (zh) 包含氘化n,n-二甲基色胺之醫藥組合物